Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole drug-interaction study with SSP-002358 in healthy adults
NL-OMON35226Phase 1Active, not recruiting
- Sponsor
- Movetis
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of revexepride in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Movetis. Primary endpoints: Pharmacokinetic parameters of SSP-002358 and Safety and tolerability. Started Aug 2011; status: active, not recruiting.
02
Drugs
revexepride
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON35226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35226.